Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases

Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases

Glecaprevir/pibrentasvir (G/P) are direct-acting antivirals (DAAs) that achieve a high sustained virological response (SVR) rate for hepatitis C virus (HCV) infection. We investigated G/P effectiveness for HCV patients based on real-world experience and the clinical features of retreatment cases. HC...

Full description

Bibliographic Details
Main Authors: Ayumi Sugiura, Satoru Joshita, Yuki Yamashita, Tomoo Yamazaki, Naoyuki Fujimori, Takefumi Kimura, Akihiro Matsumoto, Shuichi Wada, Hiromitsu Mori, Soichiro Shibata, Kaname Yoshizawa, Susumu Morita, Kiyoshi Furuta, Atsushi Kamijo, Akihiro Iijima, Satoko Kako, Atsushi Maruyama, Masakazu Kobayashi, Michiharu Komatsu, Makiko Matsumura, Chiharu Miyabayashi, Tetsuya Ichijo, Aki Takeuchi, Yuriko Koike, Yukio Gibo, Toshihisa Tsukadaira, Hiroyuki Inada, Yoshiyuki Nakano, Seiichi Usuda, Kendo Kiyosawa, Eiji Tanaka, Takeji Umemura
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Biomedicines
Subjects:
chronic hepatitis C
hepatitis C virus
glecaprevir
pibrentasvir
retreatment
Online Access:https://www.mdpi.com/2227-9059/8/4/74

Internet

https://www.mdpi.com/2227-9059/8/4/74

Similar Items